Medison Pharma and Partners Healthcare could be in line for exits after the haematological and musculoskeletal disorder therapy developer filed to raise $86.3m.
Pfizer and Lundbeck scored exits as blood-disease therapy developer Imara raised $75.2m, floating at the foot of its range.
The genetic therapy developer, which had raised $126m in funding from investors including Eli Lilly and Access Industries, added $32.4m to the offering.
The Pharmaron-backed cancer therapy developer is targeting $100m in an initial public offering preceded by $162m in funding.
Novartis and Harel are among the investors set to exit the cancer therapy developer, which also counts Bristol-Myers Squibb as a shareholder.
AIA,Tencent, Fosun, NWS Holdings and Tyan Home could exit the medical booking platform in an initial public offering valuing it at more than $10bn.
The Taiho Ventures, Memorial Sloan and Hartford HealthCare Endowment-backed cancer drug developer has filed to raise up to $86.3m.
Alibaba, Lenovo, Tuling Century and iFlytek are in line to exit the artificial intelligence chip producer, which was valued at $2.5bn as of 2018.